Evaluation of diatrizoate meglumine (Hypaque) in treatment of sudden hearing loss.
Thirty patients with sudden hearing loss were treated with diatrizoate meglumine (Hypaque) and a vasodilator regimen. Of these patients, 30% had a good response, 23% had a moderate response, and 47% had no response. These results were superior to the results obtained in a group of patients with sudden hearing loss treated with vasodilators alone. A possible mode of action is discussed and the details of a new study outlined.
D000328:Adult; D000368:Aged; D003973:Diatrizoate / Q000031:analogs & derivatives*; D003974:Diatrizoate Meglumine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006311:Hearing Disorders / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014665:Vasodilator Agents / Q000627:therapeutic use
D014665:Vasodilator Agents; D003973:Diatrizoate; D003974:Diatrizoate Meglumine